The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01.
 
JUNG-YUN LEE
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - AstraZeneca; Clovis Oncology (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); MSD; MSD (Inst); Synthon (Inst)
 
Jae-Weon Kim
No Relationships to Disclose
 
Byoung-Gie Kim
No Relationships to Disclose
 
Sang Wun Kim
No Relationships to Disclose
 
Hee Seung Kim
No Relationships to Disclose
 
Se Ik Kim
No Relationships to Disclose
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Boryung; GI Innovation; Takeda
Research Funding - AstraZeneca; CKD pharm; Clovis Oncology; OncoQuest
 
Chel Hun Choi
No Relationships to Disclose
 
Natalie Ngoi
No Relationships to Disclose
 
David Shao Peng Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Honoraria - AstraZeneca; Bayer; Eisai; Foundation Medicine; Merck; MSD; Roche; Turbine
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; GlaxoSmithKline; Merck; MSD; Roche
Speakers' Bureau - Roche
Research Funding - AstraZeneca; Bayer; Karyopharm Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Merck; Novartis; Roche
 
Yoo Na Kim
No Relationships to Disclose